Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 183 of 5804
-
New drug aims to supercharge walking recovery after spinal cord injury
Disease control Not yet recruitingBreathing brief, moderate bouts of low oxygen trigger (low oxygen therapy, LOT) spinal plasticity (the ability of the nervous system to strengthen neural pathways based on new experiences), and improve walking after spinal cord injury (SCI). The greatest improvements in walking a…
Phase: PHASE1, PHASE2 • Sponsor: Randy Trumbower, PT, PhD • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Could an arthritis drug stop a deadly skin condition?
Disease control Not yet recruitingCalciphylaxis is a rare but incredibly dangerous condition that causes small blood vessels in the skin to become blocked by calcium buildup and blood clots. This leads to painful skin sores (necrosis) that do not heal easily. Because these open wounds are prone to severe infectio…
Phase: PHASE1 • Sponsor: Boston Medical Center • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New device could free AF patients from lifelong blood thinners
Disease control Not yet recruitingThe Conscious Sedation Single Arm Sub-Study is designed to evaluate the safety and performance of the CLAAS device implantation procedure using conscious sedation.
Phase: NA • Sponsor: Conformal Medical, Inc • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Digital exercise program aims to boost recovery for breast cancer survivors
Disease control Not yet recruitingThe goal of this clinical trial is to learn if a 12-week hybrid exercise and education program (EmpowerHer) works to improve health-related quality of life in breast cancer survivors aged 35 to 65. The main questions it aims to answer are: * Does the EmpowerHer program improve …
Phase: NA • Sponsor: University of Valencia • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Could a peptide drug slow Alzheimer's? large trial launches
Disease control Not yet recruitingThe objective of this study is to evaluate the safety and efficacy of GV1001 administered subcutaneously in patients with moderate to severe Alzheimer's disease (AD).
Phase: PHASE3 • Sponsor: Samsung Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New drug aims to ease bulging eyes in thyroid disease patients
Disease control Not yet recruitingThis is a multicenter, open-label extension (OLE) study of MHB018A in subjects with moderate-to-severe TED.
Phase: PHASE3 • Sponsor: Minghui Pharmaceutical (Hangzhou) Ltd • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Can an ultrasound dye replace radiation scans for kidney scarring?
Diagnosis Not yet recruitingIn this research study the investigators want to study a safe, radiation-free technique known as contrast-enhanced ultrasound that may improve the ability to diagnose or evaluate renal scarring compared to regular ultrasound. This technique requires injection into a vein of a sma…
Phase: PHASE1 • Sponsor: Boston Children's Hospital • Aim: Diagnosis
Last updated Jul 24, 2026 00:00 UTC
-
New drug combo may shrink bleeding plaques in neck arteries, cutting stroke risk
Disease control Not yet recruitingCAROTID-STABILISE is a phase III, multicentre, randomised, double-blind, placebo-controlled trial evaluating whether alirocumab 150 mg subcutaneously every 2 weeks, added to high-intensity statin therapy, produces greater reduction in intraplaque haemorrhage (IPH) volume at 26 we…
Phase: PHASE3 • Sponsor: Middle East North Africa Stroke and Interventional Neurotherapies Organization • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Could a simple vaccine slash COPD attacks?
Disease control Not yet recruitingObjectives: To determine whether respiratory syncytial virus (RSV) vaccination reduces the rate of all-cause moderate-to-severe acute exacerbations of COPD (AECOPD) in high-risk patients, and to characterise RSV-specific infection and immune responses in this population. Hypothe…
Phase: PHASE4 • Sponsor: Chinese University of Hong Kong • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Immunotherapy plus chemo aims to fight bile duct cancer
Disease control Not yet recruitingThis is a Randomized, Open-Label, Multicenter Phase 2 Study to access the efficacy and safety of Envafolimab in Combination with Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin as the First-line Treatment in Patients with Locally Advanced or Metastatic Biliary Tract …
Phase: PHASE2 • Sponsor: 3D Medicines (Sichuan) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New targeted radiation therapy aims to improve stem cell transplants for tough myeloma
Disease control Not yet recruitingThis phase I trial investigates the side effects and best dose of ²¹¹At-OKT10-B10 when given together with fludarabine, alone or in combination with cyclophosphamide and low-dose total-body irradiation (TBI) before donor stem cell transplant in treating patients with high-risk mu…
Phase: PHASE1 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New hope for rare blood cancer: drug combo targets relapsed lymphoma
Disease control Not yet recruitingThe purpose of this study is to evaluate the efficacy and safety of sugemalimab (CS1001) in combination with PGemOx regimen (pegaspargase, gemcitabine, oxaliplatin) in treatment of adult patients with Extranodal NK/T-Cell Lymphoma (ENKTL) who have relapsed or become refractory to…
Phase: PHASE3 • Sponsor: CStone Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Emergency anthrax drug trial set to launch if outbreak strikes
Disease control Not yet recruitingThis study will evaluate safety and clinical benefit of AIGIV used for treatment of patients with inhalational anthrax. This study will be implemented only in the event of a major anthrax exposure event. The study is designed to collect information on safety, clinical benefit (su…
Sponsor: Emergent BioSolutions • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Glow-in-the-Dark dye could help surgeons wipe out sarcoma
Disease control Recruiting nowThis phase II trial compares standard of care surgical resection to fluorescence-guided surgical resection using indocyanine green and fluorescence imaging for reducing unexpected positive margin rates in patients with sarcoma. Surgical margins are one of the criteria used in ass…
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Can a community health worker program save lives in advanced HIV?
Disease control Not yet recruitingAdults who are hospitalized in Lusaka, Zambia, and found to have advanced HIV disease will be enrolled and randomly assigned to receive the ARC intervention or standard of care. All participants will then be followed through the end of the hospitalization and for up to 1 year aft…
Phase: NA • Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New drug combo aims to improve islet transplants for diabetics with kidney disease
Disease control Recruiting nowSingle arm- subject treated with Tegoprubart and everolimus. The purpose of this research is to gather information on the safety and effectiveness of investigational regimen containing 2 experimental components: * An investigational drug called Tegoprubart and * Human pancreati…
Phase: PHASE1, PHASE2 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Can a simple blood thinner save teens from deadly clots?
Prevention Not yet recruitingCritically ill adolescents are at greatest risk for developing hospital-acquired venous thromboembolism. To date, no phase 3 randomized controlled trials have been conducted for pharmacological thromboprophylaxis as primary venous thromboembolism prevention in children. The inves…
Phase: PHASE3 • Sponsor: Johns Hopkins All Children's Hospital • Aim: Prevention
Last updated Jun 27, 2026 12:37 UTC
-
Can a silent word ease both PTSD and chronic pain? a VA trial puts mantram repetition to the test
Symptom relief Not yet recruitingApproximately 450,000 Veterans Health Administration service users have both posttraumatic stress disorder (PTSD) and chronic pain (CP); treatments that efficiently target both PTSD and CP are limited, and new interventions should address the unique needs of Veterans with PTSD/CP…
Phase: PHASE2 • Sponsor: VA Office of Research and Development • Aim: Symptom relief
Last updated Jul 26, 2026 00:00 UTC
-
New drug combo takes on rare, Drug-Resistant lung bug
Disease control Not yet recruitingThe goal of this clinical trial is to learn if a new combination antibiotic treatment (Arm D) works to treat a rare lung condition called mycobacterium abscessus pulmonary disease in people of any age and sex, when compared to the standard treatments. It will also learn about the…
Phase: PHASE2 • Sponsor: The University of Queensland • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Could an immunotherapy drug keep early lung cancer from returning?
Disease control Recruiting nowThis phase III trial compares the effect of atezolizumab (or atezolizumab and recombinant human hyaluronidase) to standard observation for preventing cancer return after surgery (recurrence) in patients who have undergone a complete surgical removal (resection) of stage I non-sma…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC